Adefovir dipivoxil, a nucleotide analogue, is indicated for the treatment of hepatitis B infection in individuals 12 years of age and over. Adefovir dipivoxil is a viral suppressant. However, the drug cannot cure and prevent the transmission of hepatitis B.
No information available
No information available
No information available
Adefovir dipivoxil can cause hypersensitivity, diarrhoea, fatigue, fever, nausea, vomiting, increased cough, metabolic acidosis, shallow breathing, myalgia, drowsiness and dizziness.
Do not stop taking Adefovir dipivoxil unless advised by a physician. It can cause worsening of symptoms and fatal results. Adefovir dipivoxil is contraindicated in renal disorder patients, HIV/AIDS patients, liver transplanted patients and obese individuals.
No information available
Adefovir dipivoxil may interact with aminoglycosides, tenofovir, tacrolimus, NSAIDs, vancomycin, cyclosporine and amphotericin-B.
No information available
For treatment of chronic Hepatitis B:
Start with an oral initial dose of 10 mg, once daily. The treatment can be continued or discontinued based on therapeutic response.
Can be taken before or after food intake
USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are in gestation or planning to have a baby during Adefovir dipivoxil treatment.
It is not known whether Adefovir dipivoxil can pass through the breast milk or not. Nursing mothers should avoid breastfeeding while taking Adefovir dipivoxil.
Adefovir dipivoxil is not recommended for children less than 12 years of age.
No information available
No information available
No information available
No information available
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.